Thomas Scott Stroup

Thomas Scott Stroup

Auto-generated profile, based on publicly available information

Thomas Scott Stroup

Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 September 2005 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
JLJeffrey A. Lieberman
Jeffrey A. Lieberman
TST. Scott Stroup
T. Scott Stroup
JMJoseph P. McEvoy
Joseph P. McEvoy
MSMarvin S. Swartz
Marvin S. Swartz
RRRobert A. Rosenheck
Robert A. Rosenheck
JHJohn K. Hsiao
John K. Hsiao
The relative effectiveness of second-generation (atypical) antipsychotic drugs as compared with that of older agents has been incompletely addressed, though newer agents are currently used far more commonly. We compared a first-generation antipsychotic, perphenazine, with several newer drugs in a double-blind study.

1 October 2015 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
BVBjarni J. Vilhjálmsson
Bjarni J. Vilhjálmsson
JYJian Yang
Jian Yang
HFHilary K. Finucane
Hilary K. Finucane
AGAlexander Gusev
Alexander Gusev
SLSara Lindström
Sara Lindström
WZWei Zheng
Wei Zheng

1 December 2015 in JAMA Psychiatry
Verified
Journal Article
Open access
PDF file
MOMark Olfson
Mark Olfson
TGTobias Gerhard
Tobias Gerhard
CHCecilia Huang
Cecilia Huang
SCStephen Crystal
Stephen Crystal
TST. Scott Stroup
T. Scott Stroup
Adults with schizophrenia are at markedly increased risk of premature death.1,2 Despite elevated rates of suicide and other unnatural causes of death, most of the excess mortality has been attributed to cardiovascular disease, respiratory disease, and other natural causes.3 One analysis from the United Kingdom found that suicide, homicide, and accidental deaths collectively accounted for 21 of 164 schizophrenia deaths.4 Accurate characterizations of premature mortality patterns are important to inform clinical and policy initiatives to improve services and reduce preventable deaths in this patient population.

12 October 2006 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
LSLon S. Schneider
Lon S. Schneider
PTPierre N. Tariot
Pierre N. Tariot
KDKaren S. Dagerman
Karen S. Dagerman
SDSonia M. Davis
Sonia M. Davis
JHJohn K. Hsiao
John K. Hsiao
JLJeffrey A. Lieberman
Jeffrey A. Lieberman
Second-generation (atypical) antipsychotic drugs are widely used to treat psychosis, aggression, and agitation in patients with Alzheimer's disease, but their benefits are uncertain and concerns about safety have emerged. We assessed the effectiveness of atypical antipsychotic drugs in outpatients with Alzheimer's disease.

1 December 2005 in Schizophrenia Research
Verified
Journal Article
Closed access
JMJoseph P. McEvoy
Joseph P. McEvoy
JMJonathan M. Meyer
Jonathan M. Meyer
DGDonald C. Goff
Donald C. Goff
HNHenry A. Nasrallah
Henry A. Nasrallah
SDSonia M. Davis
Sonia M. Davis
JLJeffrey A. Lieberman
Jeffrey A. Lieberman

1 June 2007 in Archives of General Psychiatry
Verified
Journal Article
Open access
PDF file
RKRichard S. E. Keefe
Richard S. E. Keefe
RBRobert M. Bilder
Robert M. Bilder
SDSonia M. Davis
Sonia M. Davis
PHPhilip D. Harvey
Philip D. Harvey
BPBarton W. Palmer
Barton W. Palmer
JLJeffrey A. Lieberman
Jeffrey A. Lieberman
Neurocognition is severely impaired in patients with schizophrenia1,2 independent of phase of illness.3,4 While these impairments may appear prior to the onset of psychosis,5-7 their severity in patients with chronic schizophrenia is about 1.58-10 to 2.011 SDs lower than the healthy population. Neurocognitive impairment is a central clinical feature of schizophrenia, because it is strongly associated with functional outcomes.12,13